Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vigil + bevacizumab
- Development stage
- Preclinical
- Lead developer
- Gradalis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intradermal, Intravenous
01
Overview
Vigil + bevacizumab is a combination investigational cancer therapy consisting of Vigil (gemogenovatucel-T), an autologous tumor cell immunotherapy, and bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGFA). Vigil is created from a patient’s own tumor cells genetically modified to express granulocyte-macrophage colony-stimulating factor (GMCSF) and suppress the immune-inhibitory transforming growth factor beta (TGF-β1 and TGF-β2) via shRNA interference. The aim is to prime the patient's immune system against cancer antigens and enhance effector T cell responses. Bevacizumab functions by blocking tumor angiogenesis and, indirectly, may also foster a more immune-active tumor microenvironment by reducing immune suppression mediated by VEGF. This combination is under investigation for synergistic efficacy, especially in ovarian cancer and other advanced solid tumors.
- Brand names
- Vigil + bevacizumab
- Other names
- gemogenovatucel-T + bevacizumab
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on Vigil + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vigil + bevacizumab.